EMERGENT BIOSOLUTIONS INC. Interest Expense, Long-term Debt
EMERGENT BIOSOLUTIONS INC. (EBS) reported Interest Expense, Long-term Debt of $2.61 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpenseLongTermDebt · last filed 2018-02-23
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for the quarter ending 2017-12-31 was $161.00K, a 84.23% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for the quarter ending 2017-09-30 was $704.00K, a 24.63% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for the quarter ending 2017-06-30 was $835.00K.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for the quarter ending 2017-03-31 was $907.00K, a 26.68% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for fiscal 2017 was $2.61M, a 19.94% decline from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for fiscal 2016 was $3.25M, a 7.82% increase from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. interest expense, long-term debt for fiscal 2015 was $3.02M.
| Period end | Interest Expense, Long-term Debt 3 month | Interest Expense, Long-term Debt 6 month | Interest Expense, Long-term Debt 9 month | Interest Expense, Long-term Debt 12 month |
|---|---|---|---|---|
| 2017-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $865.00K derived: sum of 2 quarters · filed 2018-02-23 | $1.70M derived: sum of 3 quarters · filed 2018-02-23 | $2.61M 10-K · filed 2018-02-23 |
| 2017-09-30 | $704.00K 10-Q · filed 2017-11-03 | $1.54M derived: sum of 2 quarters · filed 2017-11-03 | $2.44M 10-Q · filed 2017-11-03 | $3.47M derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-06-30 | $835.00K 10-Q · filed 2017-08-04 | $1.74M 10-Q · filed 2017-08-04 | $2.76M derived: sum of 3 quarters · filed 2018-02-23 | $3.70M derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-03-31 | $907.00K 10-Q · filed 2017-05-05 | $1.93M derived: sum of 2 quarters · filed 2018-02-23 | $2.86M derived: sum of 3 quarters · filed 2018-02-23 | $2.86M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $1.96M derived: sum of 2 quarters · filed 2018-02-23 | $1.96M derived: sum of 3 quarters · filed 2018-02-23 | $3.25M 10-K · filed 2018-02-23 |
| 2016-09-30 | $934.00K 10-Q · filed 2017-11-03 | $934.00K derived: sum of 2 quarters · filed 2017-11-03 | $2.23M 10-Q · filed 2017-11-03 | $2.29M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-04 | $1.30M 10-Q · filed 2017-08-04 | $1.36M derived: sum of 3 quarters · filed 2018-02-23 | $2.14M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $716.00K 10-Q · filed 2017-05-05 | $1.36M derived: sum of 2 quarters · filed 2018-02-23 | $2.14M derived: sum of 3 quarters · filed 2018-02-23 | |
| 2015-12-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $1.43M derived: sum of 2 quarters · filed 2018-02-23 | $3.02M 10-K · filed 2018-02-23 | |
| 2015-09-30 | $786.00K 10-Q · filed 2016-11-09 | $2.38M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |